ESPR vs. ACMR
ESPR (Esperion Therapeutics, Inc.) and ACMR (ACM Research, Inc.) are both stocks. ESPR operates in Biotechnology (Healthcare), while ACMR operates in Semiconductor Equipment & Materials (Technology). Over the past 5 years, ESPR returned -32.31%/yr vs 23.82%/yr for ACMR. At a 0.17 correlation, their price movements are largely independent.
Performance
ESPR vs. ACMR - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, ESPR achieves a -14.59% return, which is significantly lower than ACMR's 151.25% return.
ESPR
- 1D
- 0.32%
- 1M
- 0.96%
- YTD
- -14.59%
- 6M
- -21.78%
- 1Y
- 195.33%
- 3Y*
- 33.44%
- 5Y*
- -32.31%
- 10Y*
- -15.04%
ACMR
- 1D
- -3.93%
- 1M
- 35.13%
- YTD
- 151.25%
- 6M
- 148.55%
- 1Y
- 301.62%
- 3Y*
- 103.45%
- 5Y*
- 23.82%
- 10Y*
- —
ESPR vs. ACMR - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
ESPR Esperion Therapeutics, Inc. | -14.59% | 68.18% | -26.42% | -52.01% | 24.60% | -80.77% | -56.40% | 29.63% | -30.13% | 43.13% |
ACMR ACM Research, Inc. | 151.25% | 161.26% | -22.72% | 153.44% | -72.87% | 4.95% | 340.38% | 69.58% | 107.24% | -35.74% |
Correlation
The correlation between ESPR and ACMR is 0.19, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.19 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.19 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.18 |
Correlation (All Time) Calculated using the full available price history since Nov 3, 2017 | 0.17 |
Fundamentals
ESPR:
$794.28M
ACMR:
$6.92B
ESPR:
-$0.03
ACMR:
$1.33
ESPR:
1.76
ACMR:
7.08
ESPR:
$418.24M
ACMR:
$960.23M
ESPR:
$226.32M
ACMR:
$424.76M
ESPR:
$77.18M
ACMR:
$162.91M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
ESPR vs. ACMR — Risk / Return Rank
ESPR
ACMR
ESPR vs. ACMR - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Esperion Therapeutics, Inc. (ESPR) and ACM Research, Inc. (ACMR). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| ESPR | ACMR | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.71 | ||
| Sortino ratioReturn per unit of downside risk | -0.23 | ||
| Omega ratioGain probability vs. loss probability | 1.40 | 1.47 | -0.07 |
| Calmar ratioReturn relative to maximum drawdown | 3.70 | 6.56 | -2.86 |
| Martin ratioReturn relative to average drawdown | 9.18 | 16.74 | -7.56 |
Loading charts...
Drawdowns
ESPR vs. ACMR - Drawdown Comparison
The maximum ESPR drawdown since its inception was -99.37%, which is greater than ACMR's maximum drawdown of -87.23%. Use the drawdown chart below to compare losses from any high point for ESPR and ACMR.
Loading charts...
Drawdown Indicators
| ESPR | ACMR | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.37% | -87.23% | -12.14% |
Max Drawdown (1Y)Largest decline over 1 year | -53.19% | -46.34% | -6.85% |
Max Drawdown (3Y)Largest decline over 3 years | -80.94% | -58.42% | -22.52% |
Max Drawdown (5Y)Largest decline over 5 years | -96.92% | -84.81% | -12.11% |
Max Drawdown (10Y)Largest decline over 10 years | -99.10% | — | — |
Current DrawdownCurrent decline from peak | -97.26% | -9.78% | -87.48% |
Average DrawdownAverage peak-to-trough decline | -70.03% | -39.45% | -30.58% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 21.38% | 18.11% | +3.27% |
Volatility
ESPR vs. ACMR - Volatility Comparison
The current volatility for Esperion Therapeutics, Inc. (ESPR) is 1.33%, while ACM Research, Inc. (ACMR) has a volatility of 36.43%. This indicates that ESPR experiences smaller price fluctuations and is considered to be less risky than ACMR based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| ESPR | ACMR | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 1.33% | 36.43% | -35.10% |
Volatility (6M)Calculated over the trailing 6-month period | 60.77% | 61.39% | -0.62% |
Volatility (1Y)Calculated over the trailing 1-year period | 92.43% | 79.16% | +13.27% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 91.82% | 80.80% | +11.02% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 84.53% | 84.08% | +0.45% |
Dividends
ESPR vs. ACMR - Dividend Comparison
Neither ESPR nor ACMR has paid dividends to shareholders.
Financials
ESPR vs. ACMR - Financials Comparison
This section allows you to compare key financial metrics between Esperion Therapeutics, Inc. and ACM Research, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
ESPR vs. ACMR - Profitability Comparison
ESPR - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Esperion Therapeutics, Inc. reported a gross profit of 0.00 and revenue of 80.10M. Therefore, the gross margin over that period was 0.0%.
ACMR - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, ACM Research, Inc. reported a gross profit of 107.24M and revenue of 231.26M. Therefore, the gross margin over that period was 46.4%.
ESPR - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Esperion Therapeutics, Inc. reported an operating income of -6.58M and revenue of 80.10M, resulting in an operating margin of -8.2%.
ACMR - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, ACM Research, Inc. reported an operating income of 36.18M and revenue of 231.26M, resulting in an operating margin of 15.6%.
ESPR - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Esperion Therapeutics, Inc. reported a net income of -25.20M and revenue of 80.10M, resulting in a net margin of -31.5%.
ACMR - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, ACM Research, Inc. reported a net income of 17.31M and revenue of 231.26M, resulting in a net margin of 7.5%.
Frequently Asked Questions
ESPR and ACMR have a correlation of 0.19, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
ACMR has higher volatility (36.43%) compared to ESPR (1.33%). In terms of maximum drawdown, ESPR dropped -99.37% vs ACMR's -87.23%.
ACMR currently has the higher Sharpe Ratio (3.84 vs 2.13), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for ESPR and ACMR
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer